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ABSTRACT

FUNCTIONAL SIGNIFICANCE OF MTDNA CYTOSINE MODIFICATION TESTED BY
GENOME EDITING
By Jason M. Robinson
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Major Director: Dr. Shirley M. Taylor, Ph.D.
Associate Professor of Microbiology and Immunology

The field of epigenetics is gaining popularity and speed, due in part to its capability to
answer lingering questions about the root cause of certain diseases. Epigenetics plays a crucial
role in regulation of the cell and cell survival, particularly by cytosine methylation. It remains
controversial if DNMT’s which facilitate methylation are present in mammalian mitochondria
and what the functional significance they may have on modification of mitochondrial DNA.
CRISPR-Cas9 technology enabled genome editing to remove the MTS (mitochondrial targeting
sequence) from DNMT1 of HCT116 cells, purposefully minimizing effects on nuclear cytosine
methylation, while exclusively impacting mitochondrial modification. Removal of the DNMT1
MTS did not completely prevent the localization of this enzyme to the mitochondria according to
immunoblot analysis. As well, deletion of the MTS in DNMT1 revealed only a small decline in
transcription; not until removal of DNMT3B did we see a two-fold decrease in transcription from
mitochondrial protein coding genes. No significant decline in transcription occurred when a
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DNMT3B knockout also lost the MTS of DNMT1; this study is evidencing that DNMT3B is
possibly the more significant methyltransferase in the mitochondria. Our aim from this study and
future research is to clearly characterize which enzymes in the mitochondria are controlling
cytosine modifications and to understand the mechanistic complexities that accompany cause
and consequence of epigenetic modifications.
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Chapter 1: Introduction
Mitochondrial Overview
If you have ever taken a high school biology class then you probably have heard that the
mitochondrion is the powerhouse of the cell; broadly your teacher was trying to explain that
mitochondria are responsible for generating most of your cells’ energy. In more scientific terms,
mitochondria are able to convert ADP into ATP through the process of oxidative
phosphorylation, thereby providing the cell with a source of usable chemical energy [1].
The mitochondrial organelle is comprised of several components that have specialized
function. The outer membrane encloses the entire organelle and contains integral membrane proteins
called porins which are responsible for either actively or passively transporting proteins, depending
on size, into the intermembrane space [1]. The inner mitochondrial membrane divides the
mitochondrial matrix from the intermembrane space and contains import machinery with specific
transport proteins that control metabolite pathways in and out of the matrix as well as ATP synthase
and proteins involved in redox reactions [2]. The inner mitochondrial membrane is expanded by the
cristae, invaginations that lead to additional surface area thus increasing the capacity to create ATP
[2]. At the core of the mitochondrion is the matrix; this compartment is enclosed by the inner
membrane and comprises the bulk of the mitochondrial mass. The matrix houses the mitochondrial
DNA along with all the replication, transcription and translational machinery; it also contains free
ribosomes and enzymes that facilitate the reactions that produce ATP during the Citric Acid Cycle
and oxidative phosphorylation [2].
Beyond energy production, the mitochondria also play pivotal roles in cell cycle regulation,
cell growth, cell death, cellular signaling and differentiation. Mitochondria have been implicated in
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variety of diseases from cardiac dysfunction to neuromuscular myopathies, and, as a result, are
under intense scrutiny [3]. Due to recent findings, mitochondrial defects are finally being
considered for their possible correlation in children with severe autism [4]. As mitochondria join in
fundamental processes of cellular metabolism, research is starting to address the role of
mitochondrial DNA in apoptosis, aging, and complex diseases such as ALS and cancer [3][5].
Mitochondrial DNA
MtDNA is a separate, organelle-specific genome; in humans, this genome contains 16,569 base
pairs that encode 37 genes and lack noncoding regions [3]. These genes code for 2 rRNAs, 22 tRNAs
and 13 proteins that are integral components in complexes of the electron transport chain. MtDNA is
double-stranded and circular, comprised of a heavy outer strand and inner light strand [3][6] (Figure 11). The outer strand is said to be heavy because it contains more purines than the inner lighter strand
which contains more pyrimidines, which lack the extra ring structure that purines have [6].
Although it is small in comparison to the nuclear genome (3 billion base pairs) the
mitochondrial genome can contribute about 1% of the cell’s total DNA [7]; each mitochondrion
contains 1 to 15 copies of mtDNA and human cells can house thousands of mitochondria [8].
However, despite having global influence from its energy production, and other critical roles along
with having its own genome, the mitochondrion is nowhere near autonomous. Most mitochondrial
proteins, including those that are involved in organellar transcription, translation, genome regulation
and replication are transported to the mitochondria from beginnings in the nucleus [9].
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Figure 1-1. Diagram of the circular mitochondrial genome. Heavy strand with displacement
loop is illustrated in dark blue and light strand in light blue. Genes that are labeled on the outside
of the circle are associated with the heavy strand while genes on the inside are associated with
the light strand and tRNA genes are depicted in red. Figure made by Lisa Shock
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The Mitochondrial Displacement Loop (D loop)
The mitochondrial D loop carries both heavy (HSP) and light strand (LSP) promoters in
close proximity to each other. Immediately downstream of the LSP is the origin of replication
for the H strand (OH) (Figure 1-1). The D loop is believed to exist as a triple helical structure in
complex with a short LSP-driven transcript [9], which acts as primer in replication of the heavy
strand. Super-high resolution microscopy studies [33,34] indicate that relatively few genomes
within a given mitochondrion, possible only one, is engaged in replication at any time.
Transcription from both HSP and LSP is believed to operate in a similar fashion: TFAM
(Transcription Factor A Mitochondria) binds to each promoter, bending the DNA 180o through
interaction of each globular domain with specific binding sites on each promoter. The linker
region of TFAM only assumes -helical structure through interaction with DNA (Taylor and
Hackett, unpublished observations). The DNA bend induced by TFAM brings its C-terminal
domain in close proximity to the transcription start site, allowing it to recruit TFB2M
(Transcription Factor B2 Mitochondria), which partially melts the promoter region, and
mitochondrial RNA polymerase (PolRMT), and allowing initiation of transcription. Each
functional sequence domain required for replication and strand specific transcription are in very
close proximity, leading to potential structural conflict in a genome attempting to carry out
replication as well as transcription.
Implications of multiple genomes within the mitochondrion
The mitochondrion, as mentioned, contains 1 to 15 copies (genomes) of mtDNA that
code for 37 genes. Current research is leading to the hypothesis that the individual copies of
mtDNA in the mitochondrion are not working on multiple functions at the same time, and that
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each genome has specific instructions to carry out independent functional roles. It is thought that
the genomes are partitioned into either replicating, transcribing or inert, packaged within TFAMcoated nucleoids; the underlying mechanism controlling such partitioning is at present unknown.
However, this hypothesis allows for the possibility that the cell can modulate its response to
energy demands or stress by altering the balance of individual genomes engaged in each activity.
The basis of this thesis is that modulation of functional roles among the mitochondrial genomes
is controlled, at least in part, by epigenetic modification.
Epigenetics
The field of research that is starting to answer lingering questions about the root cause of
certain diseases is the field of epigenetics. Epigenetics is the study of heritable alterations in gene
expression that are not caused by a change in DNA sequence [10]. Epigenetics plays a crucial
role in regulation of the cell and cell survival, particularly by cytosine methylation [10]. It is an
important balance of methylation that must be maintained in order for the cell to display a
continual normal transcription. While not involved in any sequence change, epigenetic
modifications such as methylation are directly related to how the transcriptional machinery can
gain access to a DNA sequence and as a result controls which genes are transcribed or silenced
[11].
Epigenetic regulation in the nucleus operates on several levels; DNA
methylation/demethylation, histone modification, and assimilation of histone variants [12]. Our
studies focus on DNA methylation since mtDNA lack histones [7]. Besides regulation of gene
expression DNA methylation in the nucleus is involved in several significant processes, such as
chromosomal X inactivation, imprinting, cellular reprograming, immune system development
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http://missinglink.ucsf.edu/lm/genes_and_genomes/methylation.html
Figure 1-2. Diagram of CpG Islands. An abundance of genes in the human nuclear genome
possess upstream CG-rich areas, known as CpG islands. CpG islands, if methylated can represses
gene expression; whether it is helpful or harmful is dependent upon the functionality of the gene.
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and conservation of the genome integrity through guarding against endogenous retroviruses and
transposons [13].
In eukaryotic nuclei, DNA methylation takes place on cytosine residues at the carbon 5
position, principally in CG dinucleotides or CpG islands [13]. The main consequence of this
methylation is an inhibitory tag to repress transcription [14]. The human genome was found to
have roughly 56 million CpG sites, of which 60-80% are methylated [13]. Aberrant DNA
methylation arrangements have been linked to some human malignancies; in comparison to
normal tissue, tumor cells frequently have hypermethylation at promotor CpG islands resulting
in gene silencing, while the majority of the genome is hypomethylated [13] (Figure 1-2). In
contrast, normal genes predominantly display hypomethylation in the promotor region and
elevated intensities of methylation in the rest of the gene. The future of the epigenetic field is
promising as modifications have shown to be reversible and are established as important
therapeutic targets [15].
DNA Methyltransferases
Methylation is catalyzed by a family of enzymes termed DNA methyltransferases
(DNMTs) [16]. S-adenosyl-methionine (SAM) is a cofactor that contributes a methyl group to
the methyltransferase substrate, consequently methylating the C5 position of cytosine residues to
produce 5-methylcytosine (5mC) [7] (Figure 1-3). It is a family of five genes that comprises the
functional methyltransferase enzymes: DNMT1, DNMT2, DNMT3A/3B and DNMT3L [13].
In the nucleus the initial and preserved pattern of methylation during embryogenesis is
established by DNMT3A and 3B, otherwise called the de novo methyltransferases which show
no preference for unmethylated and hemimethylated DNA [17]. DNMT3A and 3B are the only
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active members of the DNMT3 group as DNMT3L is catalytically inactive [17], but assists
DNMT3a and 3B in their substrate recognition. DNMT2 is inactive in methylating DNA but
instead acts as an RNA methyltransferase [17]. DNMT3A and 3B are both essential for
development; DNMT3A knockout in mice causes neonatal lethality, while DNMT3B knockouts
die in utero [14]. Mutations in either DNMT3 are associated with a variety of disorders such as
Tatton-Brown syndrome, a DNMT3A de novo mutation that is characterized by overgrowth and
intellectual disabilities [18].
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Figure1-3. DNA Methyltransferases. A) Methylation is catalyzed by DNA methyltransferases
(DNMTs) on cytosines at the 5th position of the pyrimidine ring in CpG dinucleotides; Sadenosylmethionine (SAM) is the methyl donor that converts cytosine to 5-methylcytosine. In a
subsequent reaction, 5mC can be hydroxylated by the ten-eleven translocase (TET) family of
methylcytosine dioxygenases. B) The parental strand (red)of DNA has its methylation pattern
copied to the newly created strand (blue) during replication. This ensures that the gene
expression of the parental strand is passed on and is the same as the daughter strand.
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A problem arises during replication where one strand will initially lose its pattern of
methylation during each cycle, and this is where DNMT1 comes into play (Figure 1-3). DNMT1
maintains the existing pattern of methylation throughout replication and cell division [13].
DNMT1, unlike DNMT3A/3B, has a preference for hemimethylated DNA, and in addition is
highly processive, being able methylate extensive runs without releasing its substrate DNA [13].
Like DNMT3B, DNMT1 is essential for development; DNMT1 knockouts in mice are
embryonic lethal soon after gastrulation [14]. These DNMT knockout studies establish the vital
nature of DNA methyltransferases and methylation in development and survival of mammalian
cells.
Mitochondrial DNA Methylation
It has been long established what the role of DNA methyltransferases are in nuclear
DNA methylation and nuclear DNA methylation affects biological function; however the role
and presence of DNMTs in mitochondria is a particularly controversial issue that has been at
debate for almost half a century. There are disbelievers in the science community about mtDNA
being methylated and will exclaim that previous research was excessively sensitive in nature and
lacking reproducibility in their experimental methods.
In 1971, DNA methyltransferase activity was detected in the mitochondria of a
eukaryotic organism, suggesting the possibility that 5mC was present in mtDNA [19]. However,
in those same years contrary evidence was presented stating the absence of 5mC in a mammalian
model, consequently spawning the debate as to whether methylation exists in mitochondrial
DNA [17].
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Years later in 2004, researchers once again failed to observe mtDNA methylation in both
gastric and colorectal cancers [20]. Although, they did divulge that frequencies of methylation
less than 5% would not have been detected using their site-specific methylation restriction
enzyme approach. This offers additional confidence to prior studies in 1984 that studied human
fibroblasts and mouse fibroblastoids that identified methylation was present in mitochondrial
DNA at 1.5-5% and solely in CpG dinucleotides [21] compared to mammals at 60-90%.
The pro-methylation side of the argument did not come back again until 2011 when
researchers started to compile evidence for the cause. Novel methods were used by Shock et al.
to establish the existence of 5mC in mtDNA; not only did these researchers display that 5mC is
present in mtDNA but also demonstrated the presence of 5hmC, believed to be an intermediate in
demethylation, and demonstrated that DNMT1 was the enzyme responsible for this modification
[22].
Possibly the most startling observation was that Shock et al. discovered a mitochondrial
isoform of DNMT1 (mtDNMT1). The isoform has a conserved in-frame mitochondrial targeting
sequence (MTS) with an alternative start site just upstream of the recognized start site for nuclear
DNMT1 [22]. A mitochondrial targeting software program (MitoProt II) predicted with >90%
probability that the targeting sequence would localize to the mitochondria. They demonstrated,
using confocal microscopy, that the mtDNMT1 MTS is able to deliver a heterologous protein
(GFP) to the mitochondria [22].
Oxidative stress can cause the two principal regulators of mitochondrial biogenesis,
proliferator-activated receptor c coactivator 1 (PGC1α) and nuclear respiratory factor 1 (NRF1)
to activate and interact; this activation up-regulates several nuclear-encoded mitochondrial genes
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[23]. Shock et al. was able to transiently transfect PGC1α, NRF1, or both together into HCT116
cells to analyze levels of mtDNMT1 by means of immunoblot. Co-transfection of both regulators
exhibited a fivefold upturn in total mitochondrial DNMT1, thus showing not only the presence of
a DNA methyltransferase in the mitochondria but additionally demonstrating biological
association to oxidative stress [22].
Coincidently, the NRF1 binding site overlaps a p53 consensus binding site [24]. This
tumor suppressor gene is known to control mitochondrial transcription, which lead Shock et al.
to explore if mtDNMT1 mRNA expression is affected when p53 is deleted. They reported a 6fold increase in mtDNMT1 transcription in p53 null MEFs and HCT116 cells, which reinforces
previous reports that p53 has a suppressive influence on expression of DNMT1 through specific
DNA binding [23].
Bisulfite modification transforms cytosine residues to uracil but leaves 5mC residues
unaffected, and is an effective tool for studying DNA methylation in the genome [7]. Using this
technique of bisulfite sequencing, a group reported that 5mC was restricted to the light strand of
the D-loop region [16]. The same group was able to show expression of both DNMT1 and
DNMT3B in mitochondria from HeLa cells, although, no other group has been able to show
DNMT3B in the mitochondria [16].
Besides DNMTs that catalyze the conversion of cytosine to 5mC, there is also a family of
enzymes that convert 5mC to 5 hydroxymethylcytosine (5hmC): ten-eleven-translocation (TET)
enzymes [7]. The TET enzymes have been functionally identified in the nucleus but translocation
of these proteins to the mitochondria remains controversial. The Taylor lab used
immunoreactivity and confocal microscopy studies to show that Tet2 but not Tet1 localized to
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the mitochondria; thus Tet2 is likely the enzyme responsible for the 5mC to 5hmC conversion
[22]. This proof complements the belief that mtDNA is not only methylated but mitochondria
contain the enzymes that allow for dynamic methylation and demethylation.
Epigenetics as an essential control mechanism within mitochondria
Previous work in the Taylor Lab has shown that increased methylation of mitochondrial
genomes increases the affinity of TFAM for promoter sequences and increases transcription
firing from both HSP and LSP in vitro and in vivo [25]. Epigenetics may therefore provide a
mechanism whereby the individual genomes of the mitochondrion are partitioned into functional
subgroups; investigating the patterns of methylation in individual genomes could characterize
whether the mtDNA is actively replicating, being transcribed or at rest. Generation of cell lines
with specific and purposefully altered patterns of methylation will be the starting point of
studying functional differences in genomes of the mitochondrion.

CRISPR/Cas9 Genome Editing
Clustered Regularly Spaced Palindromic Repeats (CRISPR)/Cas9 is a bacterial immune
system that has been adapted for use in multiple species and is rapidly becoming one of the most
prevalent methods for genome editing. The system comprises a guide RNA (gRNA) which
delivers an endonuclease, Cas9, to a specific site within the genome [26]. The gRNA contains a
scaffold sequence which specifically binds the Cas9 endonuclease and delivers it to a 20bp target
sequence [26] (Figure 1-4).
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CRISPR/Cas9 can be used to generate site specific knockouts with a unique targeting
sequence placed just upstream of a Protospacer Adjacent Motif (PAM); upon expression of the
Cas9 endonuclease, it will bind the gRNA to form a riboprotein compound [27]. Upon binding,
Cas9 will then undergo a conformational alteration which takes the molecule from an inactive
state to an active one [27]. The complex is then able to cleave the target DNA resulting in a
double-stranded break. The double-stranded break is then repaired by one of two pathways; nonhomologous end joining (NHEJ) or homology directed repair [26]. NHEJ is error-prone and
sometimes results in small insertions or deletions (INDELS) in the target DNA; this can result in
frameshift mutations leading to premature stop codons [27]. If possible, the ideal end result is a
loss-of-function mutation within the desired locus. Homologous recombination will occur at
lower frequency if a repair oligo nucleotide, with homology to the sequences surrounding the
break site are provided; this mechanism of repair is not error prone, and can be used to generate
site specific mutations, insertions or deletions.
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http://www.transomic.com/Products/CRISPR-Genome-Editing.aspx
Figure 1-4. Diagram of CRISPR/Cas9 genome editing. The Cas9 endonuclease will create a
double stranded break. There are two mechanisms of repair for the break: non-homologous end
joining (NHEJ), which generates chance insertions or deletions at the cleavage site, or
homologous recombination, which generates targeted mutations centered on DNA template.
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Possible Genomic Editing of mtDNMTs
As the interest in mitochondrial epigenetics grows and as the stack of evidence compiles
that indicates mtDNA is methylated and that mtDNMTs are of biological significance, it is of
interest to understand what the functional consequences are of mtDNMT loss. Mitochondria as
mentioned before play pivotal roles in cell signaling and the cell cycle in addition to cellular
respiration. Therefore, if DNMTs act in any way in the mitochondria as they do in the nucleus,
then assessing their functional significance can lead to understanding of what happens when any
of those cellular roles are defective.
Previous methyltransferase assays completed in the Taylor lab by Dr. Lisa Shock
provided evidence that DNMT1 and DNMT3B are active in the mitochondria (Figure 1-5).
These studies used mouse embryonic stem cells, previously generated by Li et al. [22], in which
the catalytic domains of DNMT1, DNMT3A and DNMT3B, and combinations, were knocked
out through gene targeting via homologous recombination. Mitochondrial lysates from these
cells were used in in vitro methyltransferase assays [22]. Graphical analysis of this assay shows
that DNMT1 and DNMT3B, but not significantly DNMT3A, are active in these cell lines.

Using methyltransferase assays and manipulating the mitochondrial isoform of DNMT1
that the Taylor lab has developed an approach to test the functional significance of mtDNA
cytosine modification. We used CRISPR/Cas9 to perform genome editing to construct innovative
cell lines lacking the DNMT1 MTS as well as in combination with DNMT3B KO cell lines.
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Figure 1-5. Methyltransferase assay. Previous work done by Dr. Lisa Shock in mouse
embryonic stem cells. A Fluorometric EpiQuik DNMT Activity Assay Ultra (Epigentek) was
used to measure activity in 10ug of protein from isolated mitochondria. Deletion of DNMT’s
catalytic domain was accomplished through gene targeting and homologous recombination.
Heterozygous and homozygous knockouts of DNMT1 were investigated along with DNMT3A
and DNMT3B knockouts with TKO being a deletion of all three methyltransferases. This data
displays that DNMT3B is active in the mitochondria.
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We reasoned that upon removal of the MTS of DNMT1, methyltransferase activity in the
mitochondria will decrease. In addition, we proposed that the removal of the MTS of DNMT1 in
a cell lacking DNMT3B activity would reduce mitochondrial methyltransferase activity even
further. We hypothesized that these changes in mitochondrial methyltransferase activity would
lead to changes in levels of DNA modification and functional output of these organelles. These
reagents would be critical in determining whether mtDNA epigenetic modification is a
mechanism whereby the functional partitioning of genomes within the organelle is dynamically
controlled in response to the energetic needs of the cell.
This hypothesis was tested by
1) Methylation analysis using methylated DNA Immunoprecipitation (MeDIP),
specifically within the mitochondria.
2) Mitochondrial Purification and Immunoblot Analysis of DNMT levels.
3) Mitochondrial Transcription analysis using RT-PCR.
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Chapter 2: Methods
Cell Culture
HCT116 (CRL 1165) neomycin resistant wild-type, HCT 3BKO (gift from Dr. Bert
Vogelstein, Johns Hopkins University) and genome edited derivative cell lines were grown at
37oC in 5% CO2 in RPMI 1640 media (Gibco/Life Technologies) containing 10% fetal bovine
serum. For all experiments performed, cells were fed 48 hours before harvest, trypsinized and
replated 24 hours before harvest, identically to ensure consistency. DNMT1 is cell-cycle
regulated so it was critical to harvest using this method to ensure that the bulk of the cells were
in S-phase, where DNMT1 levels are at their peak.
Cellular Fractionation
To obtain purified mitochondria, crude whole cell lysates and cytosolic fractions, cells
were harvested from 3x150mm dishes. The cells were washed two times with chilled 1x PBS,
pH 7.4 while on ice. Cells were scraped from the dish and transferred to a pre-weighed 15ml
conical tube (BD Falcon). An aliquot of 10% percent from each cell line was separately
reserved, pelleted and stored at -80oC for generation of whole cell lysate. The remaining cells
were then pelleted and a whole cell pellet weight was acquired. Three mL of fresh mitochondrial
homogenization buffer (10mM Tris-HCl, pH7, 0.25M sucrose, and 1mM EDTA, pH 6.8)
containing 1 tablet complete protease inhibitors (Complete EDTA-free Protease Inhibitor
Cocktail tablets, Roche) per 25ml buffer were added to resuspend cell pellets. The suspended
cells were conveyed into a chilled 7ml glass dounce homogenizer and kept on ice for 5 minutes
to permit cells to swell in the hypotonic homogenization buffer. Three series of douncing (15
down and up strokes per series) were performed, each followed by a 2,200rpm centrifugation for
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5 minutes at 4oC. The post-nuclear supernatant that contained the cytosolic and mitochondrial
fractions were saved after centrifugation. The remaining unbroken nuclear pellet was
resuspended and subjected to douncing until three series were complete. The pooled post-nuclear
supernatant was again centrifuged to pellet any contaminating nuclear fraction and collected in a
14ml round-bottom tube (BD Falcon). The supernatant was then centrifuged at 9,000 rpm for 15
minutes at 4oC to obtain a crude mitochondrial pellet with the supernatant retained to prepare the
cytosolic fraction.
The mitochondrial fraction was further purified by taking the crude mitochondrial pellet
and adding 1mL of homogenization buffer with protease inhibitors and centrifuging for 9,000
rpm for 15 minutes at 4oC two times to wash the pellet. The pellet was then washed again as
before but without protease inhibitors and resuspended in a volume 10 times the pellet weight in
Tyrpsin Digestion Buffer (250mM Sucrose, 2mM EDTA, .5mM EGTA, 10mM HEPES-KOH
and 1mM DTT). Typsin-EDTA (Gibco) 100µg/mL was added to reach a final concentration of
10µg/mL. Samples were held at 21oC for 20 minutes with intermittent gentle inversion to mix
contents. After incubation, bovine trypsin inhibitor (Sigma) 1mg/mL was added to a final
concentration of 10µg/mL; tubes were inverted to mix and placed on ice for 10 minutes. The
contents were then centrifuged at 9,000 rpm for 10 minutes at 4oC to pellet intact mitochondria.
The pellet was then washed twice with 1mL of homogenization buffer with protease inhibitors
and 10µg/mL bovine trypsin inhibitor and centrifuged as before. The final mitochondrial pellet
was resuspended and vortexed in SDS Lysis Buffer at 10 times the pellet weight and stored at 20oC.
The cytosolic fraction was further purified by acetone precipitation. Acetone was added
to cytosolic fraction at 4x volume and held at -20oC overnight. Tube was then centrifuged at max
20

speed for 15 minutes at 4oC. Cytosolic pellet was then separated from the supernatant and airdried for 10 minutes. The cytosolic pellet was then resuspended in 100µl SDS Lysis Buffer and
stored at -20oC.
The whole cell lysate was prepared by centrifuging 2500rpm at 4oC for 5 minutes and
PBS removed. The pellet was then resuspended in SDS Lysis Buffer at 7.5x volume and passed
through a 21G needle to obtain a homogenous lysate, and then stored at -20oC.
Immunoblotting
Protein concentration for lysates was determined using a Bradford assay. A standard
curve was made with known concentrations of BSA and was used to determine the protein
concentration of the protein lysates. The assay was quantified using a Genesys 10uv
spectrophotometer (Thermo). Samples were loaded onto 4-20% SDS-PAGE precast gels. 30µg
of protein were loaded for whole cell lysate comparisons. 75µg of whole cell lysate, 25µg of
cytosolic lysate and 18µg of mitochondrial lysate were loaded for subcellular fractionation
comparisons, to approximate loading of equal cell equivalents. The required volume of lysate
was then mixed with an equivalent volume of Laemmli buffer+ 5% BME. Samples were then
boiled for 10 minutes without placing on ice prior to being loaded into a gel. Samples were
loaded alongside 6 μL of Precision Plus Dual Color ladder (BioRad). The gels were
electrophoresed at 120V for ~1 hour in 1x running buffer (25mM Tris base,0.1% SDS, 250mM
glycine in 1L total volume). Resolved proteins were then transferred to an Immobilon-FL PVDF
membrane in transfer buffer, consisting of 200mL methanol, 700mL ddH2O and 100 ml 10X
transfer buffer (16.879g TrisHCl, 144.134g Glycine, 10g SDS, 17.299g Tris Base). The gel was
rinsed with ddH2O and transferred to the 1x transfer buffer for 15 minutes at 4°C for
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equilibration. The membrane was activated in methanol for ~1 minute and washed with ddH2O
for ~1 minute prior to being transferred into 1x transfer buffer for 15 minutes at 4°C for
equilibration. The transfer apparatus (gel, membrane, transfer plate, sponges, Whatman paper)
was carefully assembled and placed in the transfer box with 1x transfer buffer at 4oC and transfer
was carried out for 1 hour at 100V. After the transfer was complete the apparatus was
disassembled and the membrane was washed for 1 minute with ddH2O and then activated in
methanol for 30 seconds. The activated membrane was then ready to be checked for a positive
transfer with Ponceau stain (Bio-Rad); 2 minute soak then visualize when slowly rinsing off with
ddH2O. The washed membrane was then placed in StartingBlock T20 (ThermoFisher) overnight
at 4oC with shaking. The appropriate primary antibody diluted in StartingBlock T20 was then
added to the membrane with light shaking at room temperature for 1 hour. After primary
antibody the membrane was washed three times with 1x TBS-T (0.5M Tris-HCl, 2.7mM KCl,
0.14M NaCl and 0.1% Tween 20) with heavy shaking for 15 minutes. The membrane was then
lightly shaken in the appropriate secondary antibody diluted in StartingBlock T20 for 1 hour at
room temperature. After the secondary antibody incubation the membrane was washed again in
1x TBS-T as before. The membrane was then blotted dry to remove excess buffer and
SuperSignal West Dura (Pierce) was added so the blots could be developed on a Li-Cor Odyssey
system.
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Table 1: List of antibodies and optimal conditions.
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CRISPR/Cas9 Genome Editing
In order to create a frame-shift mutation within the MTS a single guide RNA was created,
which, along with Cas9 endonuclease should cause small insertions or deletions (indels) through
the error-prone non-homologous end joining (NHEJ) repair mechanism. Several potential
gRNAs were screened for potential off-target cleavage events by blast search and using the MIT
gRNA and off-target prediction tools found at www.crispr.mit.edu/. The selected gRNA is
highlighted in yellow in Figure 2-1.
gRNAs were synthesized by extension of overlapping oligonucleotides [33] (guided
literature) and inserted into the gRNA expression vector by Gibson Assembly according to the
manufacturers protocol (New England Biolabs). Ligation reactions were transfected into
competent DH5a and clones were screened by DNA sequence analysis.
HCT116 and its derivatives (3BKO and DKO) were plated at 1x106 cells per well in a 6well plate. Transfections were carried out using polyjet lipid based transfection reagent
(SignaGen Scientific) using 2ug DNA and 3uL polyjet per well. Transfection efficiency was
determined to be >80% based on transfection of control wells with pMaxGFP. To minimize
prolonged expression of Cas9 endonuclease, cells were co-transfected with a puromycin
expression vector (pLVTHMpuro) and transfected cells selected by resistance to 1ug/ml
puromycin. Cells were replated into 150mm dishes 48 hours post-transfection, and selection was
applied 24 hours later. Additional controls included untransfected cells, and cells transfected
with pLVTHM alone.
Approximately 10 days after transfection, individual colonies were picked using
polyester-tipped sterile swabs and plated into 48well plates. To generate replica plates, clones
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were individually released with trypsin-EDTA (Gibco) and diluted into 2 additional plates. After
growth for 5-7 days, one plate was cryopreserved at -800C in 90% fetal bovine serum 10%
DMSO, one plate was harvested for DNA preparation and PCR-based screening, and one was
maintained with bi-weekly medium changes.
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cttggtactagctacaaattctgtgtatactcaagattttctagagtaggtgcaattaccccgtttta
cagatgaggacacagaggctgagccgtagtgacccacctaaggtcgtatagccagcaaatagatggag
gttggattggaactgag
gactttactcaagggctctcacaaacccttgggggcttctcgctgctttatccccatcacacctgaaa
gaatgaatgaatgaatgcctcgggcaccgtgcccacctcccagcaaaccgtggagcttggacgagccc
actgctccgcgtggggggggtgtgtgcccgccttgcgcatgcgtgttccctgggcatggccGGCTCCG
TTCCATCCTTCTGCACAGGGTATCGCCTCTCTCCGTTTGGTACATCCCCTCCTCCCCCACGCCCGGAC
TGGGGTGGTAGACGCCGCCTCCGCTCATCGCCCCTCCCCATCGGTTTCCGCGCGAAAAGCCGGGGCGC
CTGCGCTGCCGCCGCCGCGTCTGCTGAAGCCTCCGAGATGCCGGCGCGTACCGCCCCAGCCCGGGTGC
CCACACTGGCCGTCCCGGCCATCTCGCTGCCCGACGATGTCCGCAGGCGgtaggtaccatggggggga
acacggactcagggggacaggcagggcgctgggtggggggtcgcttcccctcggggtggccggtggcc
gctgctgacagacgggcgcgcatgcgtggggtggtgcggcgcgcagcggcagttggcgcgggcagggt
ggcacttccggtcgcgcgtgcccgggctgtttggcgccaaaatggaccgtggattccc
ccgtagctccctggtggctagaaactaggcggggtgggggttctcttttgatccccaaatacagcaag
ctttgggttcgtttccggggtccccttcttcaagcagcggtgggccgggctcttgactccagcttggt
cgcacaggaagtgggcagcccgcggccaacggacacccctcgggcaccggcacttcggcctccacttc
cggtgtccggcccggtccccgggggcgcttctgtggtggggggtccctcagtgcctttcccccaaagc
tgtgc

Figure 2-1. Genomic sequence surrounding exon 1 of the human DNMT1 gene.
Selected gRNA is highlighted in yellow. The screening amplicon lies between sense PCR
primer (green) and antisense primer (red). Start ATG codons are indicated in yellow and
the mitochondrial targeting sequence is in bold italics. The published transcription start site
for the nuclear isoform begins at capitalized nucleotides
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DNA Extraction and PCR Screening of genome edited cell clones
To select DNA clones for downstream application from CRISPR/Cas9 genome editing,
DNA was extracted using MyTaq Extract-PCR Kit (Bioline). An individual well from a 48-well
plate was harvested for each clone, using 50ul of MyTaq Extract buffer. Lysates were transferred
to a 1.5ml microfuge tube and vortexed. The lysates were incubated for 5 minutes at 75oC with
intermittent vortexing then deactivated by heating to 95oC for 10 minutes. Remaining cellular
debris was pelleted and the supernatant transferred to a new 1.5ml microfuge tube. The
supernatant was then diluted 10-fold in HPLC H2O for PCR analysis.
PCR reactions consisted of 1µl of diluted template, .5µl of each forward and reverse primers
(15M), 12.5µl of My Taq HS Red Mix and 5.5µl of HPLC H2O to total 25µl. The reactions
were amplified in a Mastercycler (Eppendorf) and cycling conditions were as follows: 95oC
initial denaturation phase for 3 minutes, 95oC denaturation phase for 15 seconds, 56oC (primer
dependent) annealing phase for 15 seconds and a 72oC extension phase for 20 seconds and held
at 4oC as needed.
To screen for positive clones in genome edited samples a T7 endonuclease assay was
performed. T7 endonuclease will recognize and cleave mismatches in a imperfectly matched
DNA duplex. The reactions were all performed in a Mastercycler (Eppendorf) and set up as
follows: 13µl of HPLC H2O, 2µ NEB Buffer 2 and 3µl of wild-type HCT116 amplicon.
Reactions were performed in duplicate so that a side by side comparison could be done between
wild-type and genome edited samples; 2µl of HPLC H20 were added to wild-type and 2µl of
genome edited sample were added to one of the samples for the duplicate reaction. The samples
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were placed in the Mastercycler for a round of hybridization with cycling conditions as follows:
initial denaturation at 95oC for five minutes, gradual annealing of -2 ℃ /s to 85 ℃ then -0.1 ℃/s
to 25 ℃ and held at 4oC. T7 endonuclease (NEB) (0.1units/sample) was added to each reaction
carrying a mixture of wt and genome edited amplicon, and the reactions were incubated at 37oC
for 15 minutes in the Mastercycler. Products (20ul) were mixed with 1 µL 10x DNA loading
dye and resolved on a 1% agarose gel in 1x TAE with EtBr at 80V for 30 minutes. The gels were
viewed with a FluorChem Sp (Alpha Innotech). A cleaved band on the gel would indicate a
mismatch in DNA indicative of positive genomic editing. Samples with a cleaved band were sent
out to be sequenced (Eurofins) to determine specific mutations generated.
Each clone identified to carry mutations likely to disrupt the MTS was analyzed using
Mitoprot II to increase confidence that the enzyme would not translocate to the mitochondria. In
some instances, the indel generated a new ATG codon with a measurable probability of
translocation to the mitochondria. These clones were not analyzed further.
Sub-cloning to validate purity of individual genome edited clones.
Clones carrying indels that produced the desired interruption of the mitochondrial
targeting sequence were expanded, cryopreserved, and sub-cloned to ensure purity of the cell
line. Cells were plated at a density of 100 cells/100mm dish, and individual colonies were
picked 10 days after plating as described above. Each clone was cryopreserved and analyzed for
the same indel as the parent clone. Ten sub-clones were analyzed for each parental clone and
only those for which all ten showed identical sequences were maintained for further analysis.
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RNA Isolation
RNA was isolated by harvesting HCT116 cells from one ~80% confluent 60mm dish.
The cells were then lysed in 1mL TRI Reagent (Applied Biosystems) and incubated at room
temperature for 5 min for nucleoprotein complexes to dissociate. 200µL of chloroform was
added, samples were vortexed and incubated at room temperature for 10 minutes. The samples
were then centrifuged at 12,000 x g for 10 minutes at 4oC and the top aqueous phase containing
RNA was transferred to a new tube. 500µL of isopropanol was added, samples were vortexed
and incubated at room temperature for 5 minutes. After incubation the samples were centrifuged
at 12,000 x g for 8 minutes at 4oC and the supernatant was discarded leaving a precipitated RNA
pellet. To wash the pellets 1mL of 75% ethanol was added; pellets were centrifuged for 5
minutes at 7,500 x g and the ethanol removed. The remaining RNA pellet was then air dried for 5
minutes and resuspended in 100µL RNase-free H2O.
RNA was further purified by removal of genomic DNA by DNase I (RNase free) (Life
Technologies). 10X DNase I Buffer was added to the RNA sample to make a 1X concentration
followed by adding 1µL DNase I per 1µg DNA with a 30 minute incubation at 37oC. After the
incubation period the RNA sample was heated to 75oC for 10 minutes to inactivate the DNase I.
The RNA was analyzed for contamination by agarose gel electrophoresis. ~1µg of RNA
solution was heated to 70oC for 1 minute and placed on ice before loading. The samples and a
1kb + Ladder (Invitrogen) were resolved on a 1% agarose gel in 1x TAE with EtBr for 50
minutes at 60V. The products were then analyzed for degradation (smearing) and band intensities
on a FluorChem Sp (Alpha Innotech).
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First Strand Synthesis
First strand cDNA was created with the SuperScript ™ III First-Strand Synthesis System
for RT-PCR (Life Technologies). All components used were briefly mixed and centrifuged
before being combined in a .5mL tube. Total RNA (5μg) was mixed separately with either 1µL
2µM ATP6 forward, ATP6 reverse primers or 1μL random hexamers, 1μL (10 mM) dNTP mix,
and HPLC H2O to a total volume of 10µL. Negative no template (2µL HPLC H2O) control and
positive Hela (5µg) controls were run as well. The reactions were heated to 65oC for 10 minutes
and then placed on ice for 1 minute. The cDNA synthesis mix was prepared by adding 80μL of
10X RT buffer, 160µL of 25mM MgCl2, 80µL of 0.1M DTT, 40µL of RNaseOUT™ (40 U/µl)
and 40µL of SuperScript® III RT (200U/µL). 10µL of cDNA Synthesis Mix was added to each
RNA/primer reaction and gently mixed and centrifuged. The reactions were incubated for 50
minutes at 50oC followed by termination of the reaction at 85oC for 5 minutes and then chilled
on ice. The reactions were collected by centrifugation, 1µL of RNase H was added and samples
were incubated at 37oC for 20 minutes. For long term storage, reactions were stored at -20oC.
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Table 2: Human Mitochondrial Primer Sequences.
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RT-PCR
cDNA synthesis was carried out with three different priming methods. ATP6 forward
and ATP6 reverse cDNA primers allowed measurement of independent, strand-specific
transcription from each mitochondrial promoter (HSP and LSP). For heavy strand transcription,
PCR primers located within the 16s, ND1 and Cox1 open reading frames (ORFs) were used in
separate qPCR reactions. For light strand transcription, ND6 primers were used. Nuclear genes
encoding GAPDH and Actin were used to normalize RT-qPCR data, using cDNA synthesized
with random hexamers. The reactions consisted of 10µL SsoFast Universal SYBR Green
SuperMix (BioRad), 0.75µL each of forward and reverse primers (10mM), 7.5µL HPLC H2O
and 1µL of cDNA template for a total volume of 20µL. The reactions were assembled in a 96well plate and processed on a BioRad DNA Engine Peltier thermal cycler with a built-in
Chromo4 Real-Time Fluorescence Detector. Cycles consisted of a 30 second initial denaturation
phase at 98°C, a 10 second denaturation phase at 98oC and a 20 second annealing phase based on
the Tm of the primers (56°C- 64°C) with the last three steps repeated for a total of 40 cycles. A
melting curve was made after cycling by changing the temperature from 65°C to 90°C and read
and recorded every 1°C. Final data were analyzed using the OpticonMonitor3 program.
Methylated DNA Immunoprecipitation
The effect of genome editing on mitochondrial cytosine modification was measured by
Methylated DNA Immunoprecipitation (MeDIP), using antibodies specific for 5mC and
5OHmC. To obtain methylated and hydroxymethylated DNA samples HCT116 cells were
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harvested from 2-80% confluent dishes. DNA extraction of the cells was performed using a
DNeasy Blood and Tissue Kit (Qiagen)
The DNA samples were then purified by phenol chloroform extraction and ethanol
precipitation. An equal volume of Phenol:Chloroform:IAA (25:24:1) was added to each sample,
vortexed and centrifuged at 16,000rpm for 5 minutes at 4oC. The aqueous phase was transferred
to a fresh tube and an equal volume of chloroform was added to each sample, vortexed and
centrifuged as before. Again, the aqueous phase was transferred to a fresh tube and 1/10 volume
of 3M sodium acetate along with 10µL of glycogen was added and mixed. Ethanol was added at
3X volume, samples were mixed and incubated at -80oC for 20 minutes. After incubation
samples were centrifuged at 14,000rpm at 4oC for 30 minutes. The supernatant was removed and
500µL of 70% EtOH was added to the pellet and vortexed. Again, the samples were centrifuged
at 14,000rpm at 4oC for 30 minutes and the supernatant was removed. The pellets were allowed
to air dry for 10 minutes and resuspended in 200µL HPLC H2O.
The purified DNA was then sonicated using a Diagenode Biorupter water bath sonicator
for 2-15 minutes cycles of 30 seconds on and 30 seconds off at the highest setting. 10µL from
each round of sonication plus a non-sonicated aliquot were retained from each sample and
resolved on a 1% agarose gel; this gel is a check for a 200-700bp smear indicative of proper
sonication.
To set up the IP, 4µg of purified and sonicated DNA per antibody was diluted in TE
buffer (10mM Tris, 1mM EDTA) to a total volume of 450µL. The samples were then denatured
in boiling water for 10 minutes, directly cooled on ice for 10 minutes and 0.5uL of 10X IP buffer
(1.4M NaCl, 0.5% Triton X-100, 100mM NaPO4 pH 7.0) was added in addition to 2µg of 5mC
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rabbit monoclonal (Active Motif #61255), 5OHmC rabbit monoclonal (Active Motif #39769), or
IgG control rabbit monoclonal antibody (Millipore #12-370). The tubes were then incubated
overnight at 4oC while rotating. To pre-block the Protein G Sepharose 4 Fast Flow (GE
Healthcare), 30µL per IP sample were centrifuged at 4,500 rpm for 5 minutes at 4oC and the
ethanol supernatant was removed. 400µL 0.1% PBS-BSA (10mg BSA, 10mL PBS pH 7.4) was
added to wash the beads and this wash was repeated three times. After the third wash the pelleted
beads were resuspended in an equal volume 1X IP buffer to make a 50% slurry. To block the
beads 5µg of BSA and 5µg sonicated Lambda DNA (NEB) were add per 30µL of slurry and
rotated at 4oC overnight. At the end of the overnight incubation the beads were washed three
times as before and resuspended in 1X IP buffer. To the DNA samples with antibody
approximately 30µL of beads were added to the tubes and rotated for 2 hours at 4oC. At the end
of the incubation the beads were centrifuged at 4,500rpm for 5 minutes. The supernatant from
this last step was saved in fresh tubes as inputs for qPCR; the beads were further washed three
times with 1X IP buffer and rotated at 4oC for 10 minutes. After the third wash the pelleted beads
were resuspended in 250µL Proteinase K digestion buffer (10mM EDTA, 0.5% SDS 50mM, Tris
pH 8.0) and 3.5µL Proteinase K (20mg/mL stock). The tubes were then incubated in a shaking
water bath to prevent sedimentation at 50oC for 3 hours. After the incubation the beads were
centrifuged at 4oC for 5 minutes and the supernatant that now contains the DNA retained. The
DNA samples were then subject to another phase of purification by phenol/chloroform extraction
and ethanol precipitation. The exact steps were followed as before except the last step in which
the DNA was resuspended in 75µL TE buffer not HPLC H2O.

34

End point PCR
End point PCR was executed using HotStarTaq Master Mix (Qiagen). Each reaction consisted of 12.5
µL of HotStarTaq, 1 µL of forward and reverse primers (10 µM) and 9.5 µL of HPLC H2O as a master
mix; 19µL of master mix were dispensed into individual wells per reaction and 1 µL of cDNA was added
to each appropriate well. The reactions were run in a Mastercycler (Eppendorf). Reactions were held at
95°C for 5 minutes prior to cycling. Cycles entailed a 30 second melting phase at 95°C, a 30 second
annealing phase based on the Tm of primers (56°C-64°C), and a 1 minute extension phase at 72°C for a
total of 25 cycles to assess the quality of the IP prior to qPCR. When cycling was complete the reactions
were run at 72oC for 5 minutes and held at 4oC as long as needed. Products were resolved on a 1%
agarose gel in 1x TAE with EtBr. 10 µL of the product were mixed with 1 µL 10x DNA loading dye and
ran at 80V for 30 minutes. The gels were viewed with a FluorChem Sp (Alpha Innotech) imager.
qPCR
qPCR was set up using QuantiNova SYBR Green PCR mix (Qiagen). A master mix was constructed
containing 12.5 µL of QuantiNova SYBR Green PCR mix, 1 µL of 10 µM forward and reverse primers
each and 9.5 µL of HPLC H2O per reaction. 19 µL of master mix were pipetted into each appropriate well
of a 96 well plate with 1 µL of cDNA added to each appropriate reaction. Reactions were each performed
in triplicate. The plate was processed on a BioRad DNA Engine Peltier thermal cycler with a built-in
Chromo4 Real-Time Fluorescence Detector. The samples were held at 95°C for 5 minutes prior to
cycling. Cycles consisted of a 30 second melting phase at 95°C, 30 second annealing phase based on the
Tm of the primers (56°C- 64°C) and a 1 minute extension phase at 72°C for a total of 40 cycles. A
melting curve was produced after cycling by changing the temperature from 65°C to 90°C and read and
recorded every 1°C. Final data was examined using an OpticonMonitor3 program.
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Chapter 3: Results
Targeted Mutation of The Mitochondrial Targeting Sequence of DNMT1 using
CRISPR/Cas9 Genome Editing.
Guide RNAs were developed to target close to the published mitochondrial transcription
start site of DNMT1 (Fig. 3-1), with the goal of introducing small insertions or deletions that
would disrupt the reading frame of the targeting sequence without disrupting nuclear DNMT1
expression. DNA was extracted from individual clones that were genome edited by
CRISPR/Cas9 using MyTaq Extract and PCR amplified using DNMT1 primers to initiate the
screening procedure for successful editing (Fig. 3-2); expected PCR products of wild type and
genome edited HCT116 cells were 630 bp using these DNMT1 primers. All clones illustrated
(Figure 3-2) were positive for DNMT1 PCR amplification, however in the 48-well plate that was
screened this was not universally the circumstance. Clones that failed to produce a visible band,
usually because of poor growth, were discarded. PCR amplicons where then tested for
CRISPR/Cas9 induced mutation using the T7 endonuclease assay to detect mismatches between
wild-type and putative mutant DNA. Equal amounts of wt and genome edited clone DNA were
mixed, denatured and allowed to reanneal. Annealed PCR products incubated in the absence and
presence of the T7 endonuclease, and the T7 assay products were resolved on an agarose gel
(Fig. 3-3); Predicted 630bp bands were apparent for wild-type and wt/genome edited clones
without endonuclease. Samples where apparent digestion by the T7 endonuclease took place
produced products at 400 and ~150-200 base pairs. Samples that had these lower bands indicated
a mismatch between wt and genome edited sample, these were sent out for sequencing.
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Figure 3-1. Partial human DNMT1 sequence upstream of Exon1 encoding mitochondrial
targeting sequence. Upstream of the published nuclear DNMT1 start site (ATG3) there are two
additional potential start sites (ATG1, ATG2). Guide RNA (red underline) was designed
upstream of ATG3 within the additional 101 in-frame amino acids that encode the MTS (red
lettering) to disrupt mtDNMT1 without affecting the nuclear DNMT1 protein (green lettering).

37

Figure 3-2. Verification of mtDNMT1 DNA amplicon. Agarose gel electrophoresis of PCR
assay performed to verify predicted 630bp fragment using DNMT1 primers. Lane 1, 1kb+
Ladder (Invitrogen); 2, positive control amplicon using wt DNA; 3-10, genome edited
amplicons; 11, negative (no template) control.
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Figure 3-3. Verification of mtDNMT1 mutant construct. Agarose gel electrophoresis of T7
endonuclease assay illustrating DNA amplicons run in parallel with DNA amplicons with T7
enzyme. In samples containing mismatches between wt and mutated DNA, the 630bp predicted
DNMT1 fragment (blue arrow) was digested to ~450 and ~150bp (red arrows) with T7
endonuclease fragments. Clones of prospective genome editing were selected by band intensity
difference between amplicon and amplicon with T7 enzyme along with digested smaller
fragments. Samples C3-C8 were selected for sequencing due to this criteria.
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Figure 3-4. Initial sequencing displayed novel stop codon. Sequence results from Eurofins
International of DNA amplicons from genome edited HCT116 cell line. Seq_1 is of HCT116
wild-type to contrast Seq_2 which is genome edited. The mutated DNA carries a 17 bp deletion
across the Guide RNA (grey highlight), generating a new stop codon (red). ATG 2 (green
highlight) to novel stop codon (red) alters and potentially creates an inoperable MTS.
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Initial sequence results revealed premature stop codon.
The guide RNAs’ specific targeting allowed for the Cas9 endonuclease to create a
cleavage site shortly after the transcriptional start site of mtDNMT1, thus leaving the nuclear
start site for DNMT1 unaffected. Cellular error prone repair mechanisms (NHEJ) frequently
results in small insertions or deletions around the cleavage site. In the example shown in Fig. 34, a 17 bp deletion generates a premature stop codon upstream of the nuclear start ATG, resulting
in a truncated protein from ATG1 or 2, and presumably a nonfunctioning MTS.
Immunoblot analysis of DNMT1 revealed residual mitochondrial presence of genome
edited DNMT1.
Immunoblotting was used to analyze levels of DNMT1 in whole-cell, cytosolic and
mitochondrial fractions from HCT116 wildtype and two different HCT genome edited samples.
Stringent controls were in place to ensure that cell fractionation was complete, with absence of
contamination from other fractions. An antibody for voltage-dependent anion channel (VDAC)
located on the outer membrane of the mitochondria was used to certify equal loading. AntiHistone H3 (tri methyl K4) (H3K4me3) antibody should only detect this nuclear protein in the
whole-cell lysate fraction; presence in any other fraction is indicative of nuclear contamination.
Tubulin is a globular protein that polymerizes into microtubules; it is absent from the
mitochondria and its expression should only be found in whole-cell lysate and cytosolic fractions
with its antibody. To note: the tubulin antibody even at exceptionally low concentrations is still
an extremely potent antibody and trivial amounts of detection in the mitochondrial fraction
should be carefully considered in combination with other controls as a suitably uncontaminated
fraction.
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Over the course of more than a few cell fraction experiments images on immunoblots
would fluctuate due to several possible causes. Each cell fractionation experiment improved
upon the last by adjusting technique to better control contamination. Along with technique
adjustment there would also be an adjustment in antibody concentration during blotting if
needed. Although controls started to improve throughout the runs, the common trend that could
be seen on the blot was that genome edited DNMT1 was consistently present in all lanes
including the mitochondrial fraction (Fig. 3-5) where the absence of DNMT1 was critical for
validation. The near absence of H3K4me3 in the mitochondrial fraction with the expression of
DNMT1 in all three lanes initiated a reinvestigation and revalidation of sequences for the
genome edited cell lines.
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Figure 3-5. Detection of DNMT1 in all sample lanes. Immunoblot investigating expression of
DNMT1 found at 185kD. Cellular fractionation provided whole-cell lysate, cytosolic and
mitochondrial fractions to be probed. VDAC is a loading control found only in whole-cell and
mitochondrial fractions. Tubulin is a nuclear and cytosolic contamination control that should not
be present in the mitochondria. H3K4me3 is a nuclear contamination control that should only be
found in whole-cell lysate. The presence of DNMT1 in mitochondrial lysates from the two
genome edited cell lines suggests that residual targeting activity remains despite successful
genomic editing.
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Reinvestigation of DNMT1 genome edited sequences uncovers a novel frameshift.
Primary investigation of possible CRISPR/Cas9 indels for HCT116 was performed by selecting
sequences that had insertions or deletions in multiples of one or two base pairs, in order to disrupt the
reading frame between ATG2 (mitochondrial start) and ATG3(nuclear start). Immunoblot analysis
provided evidence that DNMT1 is still able to translocate into mitochondria, suggesting that either
DNMT1 is able to translocate without a targeting sequence, as is apparently true for many nuclear
encoded mitochondrial proteins, or that residual targeting sequence remains in the engineered locus.
Translating the sequencing results shown in Fig. 3-4 does indeed show that from ATG2 and after the
17bp deletion, a novel stop codon does arise; however, translation in the reverse direction from ATG3
reveals inframe coding sequence past ATG2 to a new ATG that is in frame with ATG3. This sequence,
while different from that of the original MTS of DNMT1, is evidently able to produce a partially
functional MTS. Mitoprot II Software (calculates mitochondrial targeting probability) calculated that the
two genome edited samples ( C6 and C8: deletions in multiples of two) selected for experimentation had
a 27% chance for one and a 70% chance for the other to still be targeted to the mitochondria.
Rescreening and selection of genome edited cell line produces authentic novel stop codon.
Genome edited cell lines were rescreened by previously mentioned methods and sequenced.
Sequencing (Fig. 3-6) (19bp del) revealed several clones that had a deletion of n amino acids plus one
base pair for both HCT genome edited and 3BKO genome edited cell lines. These deletions produced
novel stop codons in the MTS region. Two clones from each cell line were selected; sequences were
translated upstream from ATG3 and analyzed as above for the presence of an engineered new upstream
ATG. These sequences were analyzed using Mitoprot II; each cell line resulted in a less than 2-3%
chance of possessing a functional MTS and no new ATG with their edited sequences (Table 3-1).
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Figure 3-6. Sequence illustration of wild-type and genome edited cell lines. Sequences are
represented as: intron 1 (blue lower case) with ATG1 and ATG 2(blue oval), new ATG (yellow),
mitochondrial targeting sequence (upper case red), ATG3 (green oval), Exon 1 (upper case
green), gRNA (underlined red), novel stop (red oval). WT (wild-type) illustrating two ATGs
inframe with nuclear ATG3 with location of gRNA. 17bp del illustrates altered sequence with
ATG1,2 inframe with novel stop; new ATG now inframe with ATG3. 19bp del illustrates altered
sequence with ATG1,2 inframe with novel stop; no ATG inframe with ATG3, presumably nonfunctional MTS.
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Table 3-1: Specification of clone mutation, outcome and probability of processing a functional
mitochondrial targeting sequence.
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Figure 3-7. Immunoblot analysis for DNMT1 expression of select genome edited cell lines.
Lane 1, Dual Color Plus Ladder: lanes 2-4, HCT116 wild-type: lanes 5-7, HCT genome edited
clone A7: lanes 8-10, 3BKO: lanes 11-13, 3BKO genome edited clone B3. Expression for
DNMT1 at 185kD in all lanes although at a reduced level in fractions that have had the MTS
deleted. WCL (whole cell lysate), CYTO (cytosolic fraction) and MITO (mitochondrial fraction).
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Immunoblot comparative analysis of DNMT1 revealed a reduction in expression levels.
Immunoblotting was performed on all selectively screened cell lines as well as HCT116
wild-type to determine DNMT1 expression (Fig. 3-7). Previous studies with an analogous
DNMT1 antibody have shown DNMT1 expression in HCT116 cells. These current results
suggest the same expression of mtDNMT1 in HCT116 wild-type and 3BKO; however, in the
genome edited cell lines there is not a complete loss of expression as predicted. In the HCT
genome edited and the 3BKO genome edited cell lines the expression of DNMT1 has been
significantly reduced.
Immunoblot analysis for the expression of DNMT3B may be more complicated than
expected.
Immunoblot analysis for DNMT3B was performed using three different monoclonal
antibodies (Fig. 3-8). The antibodies bound in similar regions so expression was predicted to be
comparable. Western blots provided on manufacturer’s website (Santa Cruz) place DNMT3B
protein anywhere from 80kD-130kD (97.5kD predicted) with identical antibodies, however there
is no report of DNMT3b in the mitochondrial fraction for this cell line. Immunoblot analysis of
the tested antibodies was variable and inconsistent. Between the three blots, DNMT3B
immunoreactivity indicates heterogeneity of size, and further analysis with other methods will be
necessary to make a definite account of DNMT3B. For each antibody, we expected to see bands
in HCT 116 wt and genome edited cell lines (WCL, cytosol and mitochondrial lysate) that were
absent from 3BKO and its genome edited derivatives. For anti-DNMT3B-F2 antibody (Fig 83A), WCL bands at >80kDa are absent from 3BKO lysates, but there is no definite band in the
mitochondrial fraction for any of these cell line. For antibody D1, 50kDa bands in mitochondrial
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extracts of HCT116 wt and derivatives are absent from 3BKO and its derivatives, but no
convincing and consistent bands are apparent in WCL (Fig 8-3B). Bands produced by antibody
G1 are present in all 4 lines (Fig 8-3C). Interestingly this antibody (Fig. 3-8 C) produced bands
in mitochondrial lysates at 37kD and ~60kD, which might represent a cleaved DNMT3B
product. Again, these bands are present across all 4 lines. These data raised concerns that the
3BKO cell line obtained from Dr. Vogelstein at Johns Hopkins might have been contaminated
with a wt line
Genotyping of 3BKO cell line validates original knock-out.
The genotype of the 3BKO cell line can be identified by wild-type specific (R2) and
mutation specific primers (R21) (IDT) (illustration in Fig. 3-9A) for PCR (performed identical as
formerly mentioned PCR methods). PCR agarose gel images (Fig. 3-9B) in HCT116 wild-type
do not produce a product for the in silico knockout sequence but do demonstrate a product for
the reverse primers in exon2 indicating an unmodified wildtype cell line with the absence of a
knock-out. In the same gel image the 3BKO cell line does not produce a product for reverse
primers in exon2 (R2) but do demonstrate a product for the reverse primers in exon21 (R21) that
create an in silico sequence indicating that there is an apparent knock-out.
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Figure 3-8. Immunoblot analysis of DNMT3B. Lane 1, Dual Color Plus Ladder: lanes 2-4,
HCT116 wild-type: lanes 5-7, HCT genome edited clone B4: lanes 8-10, 3BKO: lanes 11-13,
3BKO genome edited clone B3. Protein lysates for all blots were from same cellular
fractionation preparation and all protein amounts are consistent. H3K4me3 was run at the bottom
of each blot for contamination control. Blots A-C are DNMT3B F2, D1 and G9 antibodies
(suppliers?) respectively.
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Figure 3-9A: Diagram of expected product of wild-type and 3BKO from PCR. WT
illustrates the expected fragments (double-sided arrow) of a wild-type cell line. The reverse
primers (R2) that lay in exon 2 will be able to make an estimated ~800-1000bp fragment with
forward primers (F1,2,3) in exon 1; since exons 2-21 are present the fragment will be too large to
produce for reverse primers (R21) after exon 21 to meet up with forward primers out of exon 1.
3BKO illustrates that when exons 2-21 are knocked out (red hatching) that only reverse 21
primers with in silico sequence will be able to produce a fragment (estimated 2-3kb) with
forward primers with in silico sequence.
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Figure 3-9B. DNMT3B genotyping PCR experiment. Lane 1, 1kb+ ladder: lanes 2-7, HCT
wild-type samples with indicated forward and reverse primers: lane 8, negative control: lanes 1015, 3BKO samples with indicated forward and reverse primers. Visible bands in HCT wild-type
and 3BKO are indicative of a positive DNMT3B knock-out.
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RTqPCR shows decreased transcription among genome edited cell lines.
RT-qPCR was carried out on strand-specific cDNA of HCT116 wild-type and
genome edited cell lines. Primers for 16s RNA, ND6, Cox1 and ND1 were chosen to
assess the effect of altering mtDNMT1 levels on transcription in the genome edited cell
lines. Using total cDNA synthesized by reverse transcription with random hexamers, the
expression levels were normalized to the geometric mean of values for beta-Actin and
GAPDH.
Genome editing in the HCT116 wt background indicates modest changes in
transcription. We observed a minimal reduction in transcription of 16S rRNA (heavy
strand) from wild-type in the genome edited lines (Fig 3-10). ND1 and Cox1, two protein
coding heavy strand genes, and ND6, the only protein coding region on the light strand,
each show a 20-40% reduction in the HCT genome edited lines. In contrast, deletion of
DNMT3B reduces transcription in the protein coding regions analyzed by 2-fold; removal
of the DNMT1 MTS did not significantly change this reduced transcription.
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Figure 3-10. Mitochondrial Transcription of genome edited cell lines. Bar graph
characterizes real time RT-PCR analysis of mitochondrial genes in HCT116 and 3BKO cell
lines. The y-axis signifies normalized mRNA expression to the geometric mean of values for  Actin and GAPDH.
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Quantification of 5-methylcytosine in genome edited cell lines by means of MeDIP.
Since expression of DNMT1 was detected in mitochondrial fractions of the genome
edited cell lines at varying levels, and since DNMT3B knockout had a profound effect on
mitochondrial transcription, it was important to determine the levels of 5mC in the cell lines to
determine whether 5mC levels might be related to the levels of transcription. DNA was purified,
sheared to a length of 200-500bp and checked on an agarose gel according to protocol (Fig. 311). Challenges occurred when purifying DNA and trying to retain enough to proceed through
the IP; after several trouble-shooting experiments, it was concluded that the best way to purify
DNA with phenol-chloroform was to use a freshly prepared mixture. The phenol-chloroform
must have the right acidity for the DNA to precipitate into the organic phase while the less
neutralized RNA remains in the aqueous phase. As well, an RNase treatment step was not
original to the protocol; however, after low levels of DNA were observed on analytical gels after
sonication, it was thought that RNA might be compromising nanodrop readings. After the RNase
treatment step was added the 260/230 ratios significantly improved on the nanodrop, indicating
previous unwanted RNA was altering projected DNA quantities.
After MeDIP and a final round of DNA purification, an endpoint PCR was performed to
visualize how wild-type and genome edited samples differed by band intensity in regards to
specific antibody on an agarose gel. The endpoint PCR was also utilized to see if levels of 5mc
could be roughly quantified by comparing band intensity to a non-specific IgG control. Several
commercial preparations of IgG yielded a very high background, in many cases higher than the
signal obtained with 5mC, and we performed tests on multiple IgG preparations from different
suppliers.
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Figure 3-11. Sonication of HCT wild-type and genome edited cell lines. Lane 1: 1Kb Plus
DNA Ladder, lanes 2-7: unsonicated samples, lanes 8-13: 15 minutes of 30 seconds on 30
seconds off high power sonication, lanes 14-19: second round of identical sonication. 200-800
base pair smear in last six lanes indicate proper shearing.

57

Figure 3-12. Endpoint PCR of HCT116 wild-type and genome edited cell lines. Top segment
of the agarose gel is that of the immunoprecipitated samples; each cell line is denoted at the top
of figure and lanes of cell line are lined up by IgG, 5mc and 5hmc antibodies respectively.
Bottom segment of the gel is the concurrent input samples; even band intensity in this portion
indicates and equal amount of DNA went into the IP.
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The IgG from Millipore gave a baseline level appropriate to move forward to qPCR seen by a
higher band intensity in all IP lanes over IgG (Fig. 3-12).
Quantitative PCR was performed on all DNA samples from the MeDIP using mitochondrial
primers for HSP1, LSP and 16s rRNA, and the outcome of the assay was formulated in excel and
graphed. The first set of primers evaluated detected HSP1 (Fig 3-13); in comparison to wt HCT116
cells, the levels of 5mC in mtDNA decreased ~25% in HCT-GE cells, 60% in 3BKO cells and 75%
in3BKO-GE cells. This data is in accord with the transcription data shown in Fig 3-10, supporting
our hypothesis that reduced 5mC results in increased mitochondrial transcription. Subsequent
qPCR analysis of LSP and 16s regions, however, showed a different pattern; both LSP and 16s
amplicons demonstrated an increase This data contradicts all other evidence from the Taylor lab and
from other published works which all point to a role for both DNMT1 and DNMT3B in mtDNA
methylation, and a controlling role in mtDNA transcription from both HSP and LSP. Furthermore,
the qPCR data did not agree with the endpoint PCR. A closer look at the raw data from the qPCR
reveled inconsistencies in the readings for input samples. Since 4ug DNA are used for each IP, and
the amount of DNA precipitated is very small, we use the IP supernatants as a measure of input for
each sample. We expect each input sample qPCR reading to be very similar, and from prior
experimentation find this to be true. However, in the experiment shown in Fig 3-13, input samples
were inconsistent from experiment to experiment and varied by as much as 5-fold in some cases. A
fault in the protocol used for the process of sonication was brought to our attention after these
findings; total purified DNA was sonicated and then the concentration was adjusted, when in fact
varying concentrations of DNA as well as total volume going into sonication affects the outcome of
shearing.
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Figure 3-13: Quantification of 5mc from MeDIP. Immunoprecipitated and input DNA was
examined by qPCR with mitochondrial primers for HSP, LSP and 16S rRNA. Levels of 5-methyl
cytosine are depicted relative to input for each cell line. Data represents average of triplicate
readings ± SE. HCT GE clone B4, 3BKO GE clone B3.

60

As a result, we began a new IP experiment in which we adjusted the concentration of
DNA to equivalent totals prior to sonication. All steps after sonication were taken according to
protocol leading into qPCR; again, results for this assay were highly variable and a reason for the
variability in outcome was provisionally inaccessible. The importance of this assay in
determining the role of methylation in the mitochondria resulted in a large amount of effort in
troubleshooting the source of variability in this data; efforts were made in procurement of fresh
buffers and reagents, constructing all new primers for qPCR, quantitating and adjusting sonicated
DNA prior to IP, performing qPCR assay on different equipment, using several different
amplification reagents in qPCR, obtaining new antibodies for IP and attempting to formulate
results independently from IgG. These efforts resulted in the same unusable results.
At this point, a possible malfunction in the sonicator was brought to our attention by a
colleague. Finally, we determined that the faulty sonicator was shearing the DNA into
exceedingly minute fragments and this outcome appeared to vary from sample to sample. These
small fragments would be unable to act as template in qPCR reactions. Results of a sonication
assay (Fig. 3-14A) where HCT116 wild-type and HCT genome edited samples were of equal
concentrations and volume and processed through two separate sonication apparatuses (one outof-lab new instrument and the one in-lab old instrument) revealed significant differences.
Following the original sonication protocol we used two 15 minutes rounds of sonication on high
with 30 seconds on and 30 seconds off. Samples were withdrawn for analysis by agarose gel
electrophoresis after each round of sonication. For the out-of-lab, new sonicator, both
sonications produced bright, broad bands in the gel, ranging in size from 300-600bp with only
slight visible smearing, consistent with optimum shearing. However, the older in-lab sonicator
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showed a significant decrease in band intensity, even after a single round of sonication,
suggestive of excessive DNA degradation. This decrease in band intensity can plausibly be
explained by supposing that the in-lab sonicator is processing the samples at such a great force
that the fragments it is producing are so minute they are running right through the agarose gel.
Coincidently, results from another MeDIP came back irregular in an endpoint PCR. The
usual protocol requires 35 cycles in the Thermocycler, however, bands of equal intensity both in
the IP and Inputs were observed in the gel image (Fig 3-14B). The virtually equal intensity in the
IP lanes for the gel was something that has not been observed before and needed to be
investigated; the assay was run again at 25 cycles, in an attempt to get more semi-quantitative
data. Upon reducing the cycle number the gel image for the assay (Fig 3-14C) revealed unequal
amounts in the Input lane. These variances in Input are unacceptable to proceed to qPCR and
possibly coincides with the sonication malfunction. Reinvestigation of the gel image for the
sonication check for the corresponding MeDIP reveals what appears to be over shearing as well
(Fig. 3-14D).
As a result of these extensive quality checks, and the clear malfunction of our sonicator,
which is used by all investigators in the Cancer Center, a new bath sonicator has been ordered for
Massey Cancer Center. Once it is in place, we plan to carry out the necessary replicate assays to
allow publication of this data set.
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Figure 3-14 A-D: Evidence for inconsistent qPCR results. A: Sonication assay reveals in-lab
sonicator has sheared samples to such a small size that a 1% agarose gel cannot contain. First
round sonication usually has smear of 500-1000bp, while second round sonication usually has
smear of 200-700bp but not below. B: Endpoint PCR (35 cycles) with all input and IP samples
from MeDIP on agarose gel. IP samples showing virtually equal band intensities, inconsistent
with previous assays requiring further exploration. C: Endpoint PCR (25 cycles) with Input and
IP samples; more sensitive assay reveals uneven loading of DNA going into the MeDIP (input).
D: Sonication check of concurrent MeDIP reveals overlooked improper shearing of DNA.
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Chapter 4: Discussion
The mitochondrial targeting sequence for DNMT1 was discovered by the Taylor lab, and
understanding the functional significance of the cytosine modifications that result necessitated
disturbing the ability of the proteins responsible from entering the mitochondria. Preventing
DNMT1 from being translocated to the mitochondria without affecting the nuclear protein was
also a novel and ambitious undertaking. Both HCT116 and 3BKO cell lines were able to have
the mitochondrial targeting sequence of DNMT1 altered using CRISPR/Cas9 genome editing.
Sequence authentication displays that the deletions created with the endonuclease generate a
premature stop codon that disrupts the targeting peptide, further substantiated by mitochondrial
targeting software. Efforts to test and create these clones were substantially drawn out because of
unconventional and multiple ATP start sites. Within the case of multiple start sites it is important
to not only examine for new downstream stop codons after the novel deletion but to also make
sure that said deletion does not generate in-frame and functional new upstream start sites that
were originally out of frame. These efforts are critical for a complete understanding of the
potential outcomes when undertaking genome editing of unique DNA regions.
The immunoblots of this study build upon previous lab work that suggest again that
DNMT1 translocates to the mitochondria [22]. The expression levels of DNMT1 in the genome
edited cell lines appears to be half of that in the lines that have complete MTSs (Fig. 3-7). This
finding suggests that the MTS does carry DNMT1 to the mitochondria because it is in lanes of
all samples. However, these data suggest that the MTS it is not the sole contributor to DNMT1
translocation. The expression levels of DNMT1 in the genome edited cell lines suggest that
making the MTS nonfunctional will affect the amount of DNMT1 going into the mitochondria
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but does not yet answer any questions about the functional significance of the cytosine
modifications resulting from mtDNMT1.
Previous studies have shown that the MTS of DNMT1 possesses the capability of taking
GFP to the mitochondria [22] and that when the MTS peptide comes in contact with the outer
membrane of the mitochondria it is recognized and validated for import; that being said it is of
importance to understand that there is always a possibility that DNMT1 uses alternative methods
to translocate to the mitochondria. There are several proteins that translocate to the mitochondria
without any obvious mitochondrial import signal. These proteins are thought to translocate
through interaction with chaperones which maintain an unfolded state [31]. However, although
no studies to date have shown interaction of DNMT1 with chaperones, the idea of a chaperone
complex shuttling DNMT1 to the mitochondria should not be out of the question. Most peptides
imported into mitochondria are recognized by their N-terminal targeting sequences; however, it
is also acknowledged that many precursors have internal recognition sequences [9]. The nature
of these internal sequences have not been characterized largely because they lack consistent
arrangements [9]; the possibility of DNMT1 also containing an internal targeting sequence has
not been investigated.
The argument over whether or not DNMT3B is taken to the mitochondria will still be
debatable according to formerly presented blots. There has been only one published study where
a western blot has shown DNMT3B in the mitochondrial fraction of a cell [16]. Blots from our
current study are inconclusive. Each antibody used in this work yielded vastly different results
despite the fact that each antibody recognized similar and overlapping regions of DNMT3B.
Several publications and manufacturer datasheets using these antibodies show DNMT3B ranging
in size from 80-130kD; the predicted molecular mass, based on amino acid sequence is 97.5kD.
66

Figure 3-8A displays strong bands in the whole-cell lysate and faint bands in cytosolic fractions
at ~80kD in the HCT116 wt and the HCT genome edited cell lines; bands are absent in the
3BKO models indicating that there is a true knock-out, however there is no signal in
mitochondrial extracts, suggesting that DNMT3B does not get transported to the mitochondria to
the extent detectable by immunoblot. Figure 3-8B displays the same size band as the previous
figure however it is expressed in every sample and only in the whole-cell lysate fraction. If the
80kD band truly represents DNMT3B, then its presence in the supposed 3BKO line indicates
that this line is not a true knock-out. Interestingly there is a band at ~45kD expressed strongly in
the mitochondrial fraction of both the HCT lines and faintly in the mitochondrial fraction of the
3BKO lines. These results might indicate cleavage of DNMT3B during translocation into the
mitochondria in the HCT lines, and possible DNMT3B contamination from cytosol resulting in
the faint bands seen in the 3BKO mitochondrial extracts, perhaps due to improper technique.
Figure 3-8C is just as unique as the first two blots; there is a band in the whole-cell lysate and
cytosolic fractions of every sample at ~100kD that could be DNMT3B. Again, in the
mitochondrial fraction there is a band that could represent cleavage of DNMT3B in the import
complexes of the mitochondria at ~40kD; however Figure 3-8C displays these bands in every
sample. Several of these figures are suggestive that there is not a true knock-out of DNMT3B;
thus our genotyping experiment was crucial to characterization of this line before proceeding on
to other characterization experiments. Verification of a knock-out was attained (Fig. 3-9)
meaning that any interpretation from the immunoblots would be difficult to substantiate.
DNMT3B does not contain an N-terminal MTS as found for DNMT1. An internal
targeting sequence has not been found within DNMT3B, therefore transport to the mitochondria
or recognition of the protein at the outer membrane is questionable. N-terminal targeting
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sequences are predominantly cleaved on passage through the outer membrane [31], and, for
many proteins, multiple cleavage events occur along the length of the peptide upon passage
through the inner mitochondrial membrane. The purpose of these proteolytic cleavage events that
occur throughout the import complexes has not been identified, although some proteins have
been characterized to be cleaved at defined points to specific sizes once inside the mitochondrial
matrix. Previous work in the Taylor lab has shown immunoblots of DNMT1 expression in the
mitochondrial fraction [22]; however, there has been a consistent lower band that has not been
characterized at ~60kD. The DNMT3B immunoblots of this study sometimes display lower
bands as well in the mitochondrial fraction. It would be of significance to examine the lower
bands in current and past studies with techniques such as mass spectrometry to better identify
their relationship to the methyltransferases in the mitochondria.
RTqPCR data was more accommodating to address the functional significance of DNA
methyltransferases in the mitochondria. Across the three protein coding mitochondrial genes
tested, ND1, Cox1 and ND6, there is an apparent trend towards reduced expression, correlating
with genome editing of the MTS in mtDNMT1 alone or in conjunction with knockout of
DNMT3B. Our previously published work indicates that increased mtDNMT1 expression
results in increased mitochondrial transcription [22], and ongoing in vitro experiments in our lab
using a reconstituted system with recombinant enzymes and transcription factors, demonstrate a
3-fold increase in transcription from HSP when the 3 CG dinucleotides in and around the
promoter are methylated, in comparison to the unmethylated sequence. The 16s ribosomal RNA
gene does not showcase this trend as the difference between samples is subtle. The level of
rRNA transcription is much higher than that of protein coding mRNAs, and rRNA transcription
is believed to operate by a different mechanism that is independent of polycistronic ORF mRNA
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production [32]. ND1, Cox1 and ND6 demonstrate a significant pattern of decline amongst the
samples. In those gene sets when the MTS of DNMT1 has been genomically edited out of the
HCT116 cell line there is an overall decrease in transcription of ~27%. The most significant
decline in transcription occurs in the DNMT3B knock-out cell line, which has a decline in
transcription of ~55%. Further editing of the DNMT1 MTS in this background did not further
decrease the transcription level.
The lack of significance in the difference between the genome edited 3BKO and the
3BKO in itself could possibly mean that DNMT3B and not DNMT1 is the more functionally
significant methyltransferase in the mitochondria. Previous studies have shown in the nucleus
that in the absence of DNMT1, DNMT3B expression increases in the absence of the DNMT1
[30]. This could possibly be the same case in the mitochondria and explain that in the genome
edited cell lines the reduction in transcription is only 27% and not closer to 50%; that DNMT3B
is making up for some of the absence of DNMT1. This is possibly evident in (Fig 3-8) where one
can see a greater expression level of DNMT3B in the HCT genome edited cell line over the
HCT116 wild-type.
Endpoint PCR has been a standard checkpoint throughout multiple investigations in the
Taylor Lab and many other labs. The agarose gel image from endpoint PCR gives a basic
measurement of success from the MeDIP; however, this assay needs to be closely scrutinized as
a lower cycle number reaction can reveal discrepancies obscured with a higher cycle number, as
shown in this research. It would be essential to optimize this assay in conjunction with the
MeDIP before placing any value on the reliability as a checkpoint.
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QPCR was planned to be an essential assay in this research for measuring how genomic
modifications to methyltransferases affect levels of methylation within mitochondrial DNA. As
results proved to be highly variable, we do not yet have the necessary number of replicates for
conclusive support of our hypothesis. The principle effort of having equivalent amounts of DNA
going into the MeDIP is critical in order to have reliable qPCR data. However, we were able to
pinpoint the source of error, in the faulty sonicator. The troubleshooting to find this equipment
failure, although prolonged, did not go to waste; the protocol for the MeDIP was shortened and
made to be more efficient and precise, and the technical experience gained was invaluable.
Replacement of the faulty equipment should allow future experiments to complete this study for
publication.
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Chapter 5: Perspectives and Conclusions
There is continued controversy in the literature concerning which methyltransferases
reside in the mitochondrial matrix, largely generated because different investigators use different
antibodies with largely differing sensitivities. We chose a more specific genetic approach in
order to avoid issues of antibody detection.
The goals of this study were therefore to define which methyltransferases were present in
mammalian mitochondria and to gain understanding of the role and functional significance of
mitochondrial DNA methylation. We approached this study using CRISPR-Cas9, the new and
cutting-edge technology for genome editing to remove the MTS from DNMT1, thus minimizing
effects on nuclear cytosine methylation, while impacting mitochondrial modification. This same
approach is not possible with either DNMT3a or 3b, because they lack N-terminal MTS. Our
expectation was that depletion of mtDNMT1 would result in reduced cytosine methylation along
with reduced transcription.
To our surprise, removal of the DNMT1 MTS did not completely prevent the
localization of this enzyme to the mitochondria, raising the possibility that the enzyme can
translocate to this organelle using alternative mechanisms. Significantly reduced protein
expression of the cell lines without a DNMT1 MTS conceivably emphasize the cellular
importance of necessitating DNMT1 to be in the mitochondria; however, the transcription data
presented here supports the notion that other methyltransferases besides DNMT1 localize to
mitochondria and may be ever more functionally significant. Deletion of the MTS in DNMT1
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shows only a meek reduction in transcription, not until removal of DNMT3B do we see a twofold decrease in transcription from mitochondrial protein coding genes. As well, no significant
reduction in transcription occurred when the DNMT3B knockout also lost the MTS of DNMT1;
apparently, contrary to what we expected, DNMT3B is being evidenced to big a bigger player in
mitochondrial transcription.
DNMT3B appears to be an attention-grabbing target to further explore. Investigation into
possible processing of DNMT3B upon entering the mitochondria is evidenced by this works
immunoblots, could lead to the further convincing proof that DNMT3B is translocated to the
mitochondria. Not only could research define translocation, it could very well point towards the
mechanism of translocation. An understanding if and/or where DNMT3B is being cleaved might
expose some internal targeting sequence that could be referenced with other different proteins
that have not been able to be exposed in the mitochondria.
As an orthogonal approach to quantifying functional significance of DNA
methyltransferases to under-methylated mtDNA, the Taylor Lab has developed a completely
methylated representation; accomplished by M.Sss1 which is a CpG methyltransferase that will
methylate all CpGs. Since methylation in the mitochondria is known to be exceptionally low
compared to the nuclear genome, this over-methylation approach may give a more true
quantification. The Taylor Lab has humanized codon usage and placed the TFAM MTS at the Nterminus of M.Sss1. We found that constitutive overexpression is non-permissive since we were
not originally able to obtain stable clones. The Taylor Lab has now developed an inducible
construct of M.Sss1 and have begun to test its effect on mtDNA methylation and mitochondrial
transcription. As well, current investigation suggest that genome edited cell lines have
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differences in mtDNA copy number average compared to that of wild-type. Lab efforts have
begun to address the consistency of such differences and the most effective way to normalize
them.
Further effort will be necessary to conclude what mechanisms in the mitochondria are at
work. To really comprehend the impact of mtDNA methylation it will be critical to classify all of
the contributors involved and understand the mechanistic complexities that accompany cause and
consequence of epigenetic modifications. Genomic editing will significantly support the journey
to understanding of epigenetics of the mitochondrion. Mitochondria have been implicated in a
variety of neurodegenerative disorders and cancers and the lingering question of what is the
plausible biological function of methylation in the mitochondria needs to be answered.
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